PR Newswire·Oct 28, 2025, 9:58 AM ET

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Faruqi & Faruqi, LLP is investigating potential securities claims against Savara Inc. (NASDAQ: SVRA) following a stock price drop.
The firm reminds investors of the November 7, 2025 deadline to seek the role of lead plaintiff in the federal securities class action.
Investors who purchased Savara securities between March 7, 2024, and May 23, 2025, are encouraged to contact partner James (Josh) Wilson to discuss legal options.
The complaint alleges Savara violated federal securities laws by making false or misleading statements regarding the MOLBREEVI Biologics License Application (BLA).
Allegations state the MOLBREEVI BLA lacked sufficient chemistry, manufacturing, and controls information, making FDA approval unlikely in its current form.
Savara received a "refusal to file" letter from the FDA for MOLBREEVI on May 27, 2025, causing its stock to fall 31.69% to close at $1.94 per share.
The firm claims the regulatory delay increased the likelihood of the company needing to raise additional capital, rendering prior public statements misleading.
Any class member may move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in potential recovery.
Faruqi & Faruqi encourages whistleblowers, former employees, shareholders, and others with information on Savara's conduct to contact the firm.